-
1 Comment
NextCure, Inc is currently in a long term downtrend where the price is trading 25.1% below its 200 day moving average.
From a valuation standpoint, the stock is 99.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 12.4.
NextCure, Inc's total revenue sank by 100.0% to $0 since the same quarter in the previous year.
Its net income has dropped by 41.5% to $-15M since the same quarter in the previous year.
Finally, its free cash flow grew by 32.8% to $-7M since the same quarter in the previous year.
Based on the above factors, NextCure, Inc gets an overall score of 2/5.
| ISIN | US65343E1082 |
|---|---|
| Exchange | NASDAQ |
| CurrencyCode | USD |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | 13M |
|---|---|
| PE Ratio | None |
| Target Price | 3 |
| Beta | 0.89 |
| Dividend Yield | None |
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer's disease; and NC605 an antibody that targets Siglec-15, as well as chronic bone diseases, such as osteoarthritis and non-union fractures. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for NXTC using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
